Multiple myeloma therapies are evolving rapidly. Recently, in Portugal, the inhibition of the NFIL3-MYC axis has shown to overcome treatment resistance in high-risk patients. New approaches, such as CAR-T therapies and antibody combinations, are being explored in various countries, including Canada and the USA, with the aim of improving access to treatments.
Made by MielomaAI On November 17, 2026, at 11:05, based on recent news. May contain errors. View news →
In the last 3 months. On the site you’ll find the news from the last 3 months. The older ones only have the title and a link, in file by topicsIt’s a support website for people with multiple myeloma. It aims to keep things simple and clear. MielomaAI As you may find.
Collected from Portuguese newspapers, Google News (PT, EN, ES, FR) and associations and scientific societies. They are on the website 197 news: only from the last 3 months. The older ones are only shown with the title and link, in file by topicsAnd research and the MielomaAI You continue to find them. Always consult the original news article and speak with your doctor before drawing conclusions about your case. Last update: November 17, 2026, 3:21 PM.
Monday, 16/11
- Targeting the NFIL3-MYC Axis Overcomes Therapy Resistance in High-Risk Multiple MyelomaBioengineer.org (Reino Unido) · 22:49 TratamentosReino Unido
Cobertura jornalística abrangente e atualizada, reunida a partir de fontes em todo o mundo pelo Google News.
MRD Ready to Guide Multiple Myeloma Treatment Decisions?MedPage Today · 17:32 Tratamentos'MRD is becoming a very valuable tool, but it's not an exclusive tool,' says expert
Next-Generation Multiple Myeloma Therapies Market to ReachopenPR.com · 16:44 TratamentosNovember 16 2026 Multiple myeloma treatment is expanding across antibody combinations CAR T cell therapies and newer immune modifying drugs Recent U S approvals have brought some options into earlier treatment lines while new subcutaneous formulations are changing how antibody ...
Tempest acquires rights to experimental myeloma treatmentRare Cancer News · 16:28 TratamentosTempest Therapeutics has exercised an option to obtain rights to develop and commercialize an experimental treatment for myeloma.
Sanofi and the Alliance Pharmaceutical PanCanadian sign a letter of intent for Sarclisa® (isatuximab), a further step towards public access for newly diagnosed patients with multiple myeloma who are not eligible for a transplant.PR Newswire Canada (Canada) · 14:15 TreatmentsCan you provide the French text you want me to translate?FR/CNW/ -- Sanofi announced today the happy conclusion of negotiations with the Canadian Alliance Pharmaceutical (CPP), marked by the signing of a...
Teclistamab Plus Daratumumab in Multiple Myeloma: FDA Adverse Event Reporting System AnalysisOncodaily · 11:23 TratamentosTeclistamab Plus Daratumumab in Multiple Myeloma: FDA Adverse Event Reporting System Analysis / BCMA, BCMA × CD3 bispecific antibody, Daratumumab, FDA
MM’s Vulnerability to CAR T Was a Happy Surprise: Nikhil C. Munshi, MDThe American Journal of Managed Care® (AJMC®) (EUA) · 00:11 TratamentosEUAA single chimeric antigen receptor (CAR) T-cell infusion can clear heavily pretreated myeloma in 2 weeks, highlighting the immune system’s adaptability.
Sunday, November 15
Why Multiple Myeloma’s Standard of Care Could Change Again Within a YearCancerNetwork (EUA) · 18:05 TratamentosEUACancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.
Friday, November 13
Six jobs for AI in myeloma care, from Prerna Mewawalla, M.D.Managed Healthcare Executive · 19:24 TratamentosOnly 19% of community oncologists use AI predictive models. Prerna Mewawalla, M.D., outlines six ways AI can already help in myeloma care.
Warburg Trap Therapy Selectively Triggers Apoptosis in Multiple Myeloma Cells in VitroBioengineer.org · 14:25 TratamentosA laboratory study demonstrates that combining mitochondrial complex I inhibitors with proton ionophores selectively triggers apoptosis and disrupts energy balance in multiple myeloma cells in vitro.
My Treatment Approach: Optimizing Treatment Strategies for Relapsed/Refractory Multiple MyelomaOncLive (EUA) · 13:00 TratamentosEUAMy Treatment Approach: Optimizing Treatment Strategies for Relapsed/Refractory Multiple Myeloma | OncLive Insights | OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Thursday, November 12th
Referral Before Salvage Therapy Keeps CAR T an Option in MyelomaTargeted Onc (EUA) · 22:08 TratamentosEUADuring a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
How Etentamig Stands Out From Other BCMA BispecificsTargeted Onc (EUA) · 22:00 TratamentosEUAPeter Voorhees, MD, explains how etentamig differentiates itself from other BCMA bispecifics for multiple myeloma through a strategic engineering choice: a low-affinity CD3 binding domain. By intentionally reducing this affinity, the design aims to mitigate severe cytokine release syndrome. It can also be given on an…
CELMoDs as Holding and Bridging Therapy in Multiple MyelomaCancerNetwork (EUA) · 15:43 TratamentosEUAIn this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith explore the potential role of cereblon E3 ligase modulators (CELMoDs) as holding and bridging therapies for patients with multiple myeloma preparing for chimeric antigen receptor (CAR) T-cell therapy.
CELMoDs With CAR T-Cell Therapy and Bispecific Antibodies in Multiple MyelomaCancerNetwork (EUA) · 13:13 TratamentosEUAIn this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss the potential role of cereblon E3 ligase modulators (CELMoDs) following chimeric antigen receptor (CAR) T-cell therapy and in combination with bispecific antibodies for multiple myeloma.
Wednesday, 11/11
Real-World Teclistamab Shows Deep Responses in R/R Multiple Myeloma CohortCancerNetwork (EUA) · 20:08 TratamentosEUAIn a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
Doctor from Santa Rosa participates in immersion on the treatment of multiple myeloma in the United States.Jornal Noroeste (Brazil) · 17:00 TreatmentsBrazilPTThe event, held in an immersive course format, brought together teachers and specialist doctors in the field within a program that included lectures, visits to reference centers, and discussions about diagnostic and therapeutic approaches for multiple myeloma, a type of cancer that affects plasma cells in the bone marrow…
- Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D CandidateGlobeNewswire (Internacional) · 13:53 TratamentosInternacional
-Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates -Lead BCMA/GPRC5D...
Legend Biotech shares tumble as Carvykti outlook overshadows profitBamboo Works · 04:23 Tratamentos
Tuesday, November 10
Gilead at Wolfe Healthcare Conference: anito-cel launch in focus By Investing.comInvesting.com India (EUA) · 17:07 TratamentosEUA
Monday, November 9th
Melflufen Gains EU Expansion in Third-Line Lenalidomide-Refractory Multiple MyelomaOncLive (EUA) · 21:41 TratamentosEUAThe decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.
BCMA-Directed Bispecifics and ADCs Broaden Treatment Sequencing Options in R/R MyelomaOncLive (EUA) · 14:06 TratamentosEUADuring a recent OncLive Peer Exchange, multiple myeloma experts discussed how BCMA-directed therapies can be selected and sequenced.
Friday, November 6th
IDP-023 Plus Isatuximab Drives Responses in Daratumumab-Refractory Multiple MyelomaOncLive (EUA) · 08:00 TratamentosEUAIDP-023 plus isatuximab was tolerable and generated responses in heavily pretreated relapsed/refractory multiple myeloma.
Wednesday, 11/04
Treatment After Early Relapse and Real-World Evidence in Relapsed/Refractory Multiple MyelomaOncLive (EUA) · 08:00 TratamentosEUAThe panel discusses treatment strategies for patients with relapsed/refractory multiple myeloma who experience early disease progression following BCMA-directed therapy, including CAR T-cell therapy.
Emerging Therapies and Supportive Care Advances in Relapsed/Refractory Multiple MyelomaOncLive (EUA) · 08:00 TratamentosEUAThe panel looks ahead to emerging developments that may continue to shape treatment of relapsed/refractory multiple myeloma.
Modern rises 8% on early multiple myeloma data for its three-in-one mRNA therapy.TIKR.com · 08:00 TreatmentsPTSmall trial, big idea.
Tuesday, November 3rd
T-Cell Fitness and Treatment Sequencing in Multiple MyelomaCancerNetwork (EUA) · 08:00 TratamentosEUAIn this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss how T-cell fitness may influence treatment sequencing in multiple myeloma, particularly as chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies become increasingly important treatment options.
Multiple myeloma: new therapies raise discussion about the possibility of a cure for the diseaseVEJA (Brazil) · 08:00 TreatmentsBrazilPTImmunotherapies and other innovations are expanding the chances of deep and lasting responses.
Chongqing drugmaker launches China's first domestically developed BCMA/CD3 bispecific antibodyChina Daily (China) · 08:00 TratamentosChina
Advanced imaging tool improves detection of residual multiple myeloma diseaseNews-Medical (Internacional) · 08:00 TratamentosInternacionalA targeted immunoPET scan detected active multiple myeloma that standard PET/CT scans and blood tests missed, a finding that could help doctors more accurately map disease, guide treatment decisions and confirm whether cancer remains after therapy.
Early Relapsed Myeloma: No Efficacy Hierarchy Established Between CAR T Cells and Bispecific AntibodiesOncodaily (Reino Unido) · 08:00 TratamentosReino UnidoEarly Relapsed Myeloma: No Efficacy Hierarchy Established Between CAR T Cells and Bispecific Antibodies / Bispecific antibodies, cancer, CAR-T, Headlines,
High-Risk Multiple Myeloma Linked to Earlier CAR-T Cell FailureEMJ (Reino Unido) · 08:00 TratamentosReino UnidoHigh-risk multiple myeloma features were associated distinct patterns of treatment failure after cilta-cel.
Monday, 02/11
Frontline Treatment in Multiple Myeloma Is ChangingMedPage Today (EUA) · 08:00 TratamentosEUAExperts discuss the broader use of four-drug regimens and whether treatment can be shortened
Sunday, November 1st
Myeloma Is Many Diseases, and Treatment Must Reflect ThatThe American Journal of Managed Care (EUA) · 07:00 TratamentosEUANikhil C. Munshi, MD, says 25% to 30% of patients with myeloma may now be cured, but relapse and access remain challenges.
Thursday, October 29th
Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?CancerNetwork (EUA) · 17:09 TratamentosEUA“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Dr. Rahul Banerjee on the future of myeloma careFred Hutchinson Cancer Center (Reino Unido) · 07:00 TratamentosReino UnidoRahul Banerjee, MD, FACP joins Petros Grivas, MD, PhD to discuss how CAR T cell-therapy and bispecific antibodies are changing myeloma care, ongoing Fred Hutch trials, working with community oncologists, and the team approach behind it all.
Starton Therapeutics Signs Clinical Trial Agreement with the Stanford School of Medicine to Evaluate STAR-LLD in Combination with Novel CAR-T Therapy for Multiple MyelomaBusiness Wire (Internacional) · 07:00 TratamentosInternacional
